- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 4779
View more information in the IUPHAR Pharmacology Education Project: metformin
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Used in the management of non-insulin dependent type 2 diabetes as an adjunct to diet and exercise. Also used in the management of polycystic ovary syndrome (PCOS).
Metformin is combined with canagliflozin in Invokamet®, (also marketed as Vokanamet®) the first fixed-dose combination of an SGLT2 inhibitor with metformin to be approved (by the US FDA, 2014). Later in 2014, the US FDA approved a second SGLT2/metformin drug, Xigduo XR®, which contains dapagliflozin (as dapagliflozin propanediol monohydrate PubChem CID 56841155) and metformin hydrochloride. The first approval of a metformin-containing drug mixture by the EMA was for Avandamet (rosiglitazone plus metformin), although this drug was later withdrawn from the market. Avandamet has been superceeded by newer and more effective anti-diabetes combination drugs.
|Mechanism Of Action and Pharmacodynamic Effects|
|Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut, which appear to rely on metformin-induced activation of AMP-activated protein kinase (AMPK).|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)